120 related articles for article (PubMed ID: 6265342)
41. [Adenylate kinase deficiency].
Matsuura S; Nakazawa A
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):610-4. PubMed ID: 2855949
[No Abstract] [Full Text] [Related]
42. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility.
Baur CP; Bellon L; Felleiter P; Fiege M; Fricker R; Glahn K; Heffron JJ; Herrmann-Frank A; Jurkat-Rott K; Klingler W; Lehane M; Ording H; Tegazzin V; Wappler F; Georgieff M; Lehmann-Horn F
Anesth Analg; 2000 Jan; 90(1):200-5. PubMed ID: 10625004
[TBL] [Abstract][Full Text] [Related]
43. Xenon does not induce contracture in human malignant hyperthermia muscle.
Baur CP; Klingler W; Jurkat-Rott K; Froeba G; Schoch E; Marx T; Georgieff M; Lehmann-Horn F
Br J Anaesth; 2000 Nov; 85(5):712-6. PubMed ID: 11094586
[TBL] [Abstract][Full Text] [Related]
44. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
[TBL] [Abstract][Full Text] [Related]
45. A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia.
Ginz HF; Rüffert H; Levano S; Li Wan Po A; Benthien J; Urwyler A; Girard T
Pharmacogenet Genomics; 2009 Dec; 19(12):972-8. PubMed ID: 19890226
[TBL] [Abstract][Full Text] [Related]
46. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
47. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
48. Electrophoresis of muscle proteins is not a method for diagnosis of malignant hyperthermia susceptibility.
Walsh MP; Brownell AK; Littmann V; Paasuke RT
Anesthesiology; 1986 Apr; 64(4):473-9. PubMed ID: 3963453
[TBL] [Abstract][Full Text] [Related]
49. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
[TBL] [Abstract][Full Text] [Related]
50. Malignant hyperthermia susceptibility without central core disease (CCD) in a family where CCD is diagnosed.
Islander G; Henriksson KG; Ranklev-Twetman E
Neuromuscul Disord; 1995 Mar; 5(2):125-7. PubMed ID: 7767091
[TBL] [Abstract][Full Text] [Related]
51. Screening for malignant hyperthermia susceptibility.
Anderson IL; Rawstron RE; Dunlop DJ
N Z Med J; 1980 Jun; 91(661):417-9. PubMed ID: 6930029
[TBL] [Abstract][Full Text] [Related]
52. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ
Lancet; 1991 Dec; 338(8781):1491-2. PubMed ID: 1683922
[TBL] [Abstract][Full Text] [Related]
53. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
[TBL] [Abstract][Full Text] [Related]
54. Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test.
Anetseder M; Hager M; Müller CR; Roewer N
Lancet; 2002 May; 359(9317):1579-80. PubMed ID: 12047971
[TBL] [Abstract][Full Text] [Related]
55. Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test?
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyford HG; Dupuis BA
Anesth Analg; 1992 Jan; 74(1):105-11. PubMed ID: 1734769
[TBL] [Abstract][Full Text] [Related]
56. Malignant hyperthermia: update on susceptibility testing.
Litman RS; Rosenberg H
JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
[TBL] [Abstract][Full Text] [Related]
57. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
Glauber V; Ben Abraham R; Zweig A; Perel A
Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136
[TBL] [Abstract][Full Text] [Related]
58. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
[TBL] [Abstract][Full Text] [Related]
59. Malignant hyperthermia in dogs.
Nelson TE
J Am Vet Med Assoc; 1991 Mar; 198(6):989-94. PubMed ID: 2032926
[TBL] [Abstract][Full Text] [Related]
60. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
